Lucid Diagnostics Inc (NASDAQ:LUCD) — Market Cap & Net Worth
Market Cap & Net Worth: Lucid Diagnostics Inc (LUCD)
Lucid Diagnostics Inc (NASDAQ:LUCD) has a market capitalization of $149.02 Million ($149.02 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17774 globally and #4194 in its home market, demonstrating a -4.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lucid Diagnostics Inc's stock price $0.78 by its total outstanding shares 190948730 (190.95 Million). Also see LUCD total asset value for a full breakdown of the balance sheet.
Lucid Diagnostics Inc Market Cap History: 2021 to 2026
Lucid Diagnostics Inc's market capitalization history from 2021 to 2026. Data shows change from $1.03 Billion to $149.02 Million (-42.33% CAGR). Also see Lucid Diagnostics Inc (LUCD) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Lucid Diagnostics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #491 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1738 of 3165 |
Weight: Lucid Diagnostics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lucid Diagnostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lucid Diagnostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Lucid Diagnostics Inc (LUCD) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
44.23x
Lucid Diagnostics Inc's market cap is 44.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.03 Billion | $500.00K | -$28.08 Million | 2050.79x | N/A |
| 2022 | $259.69 Million | $377.00K | -$56.17 Million | 688.83x | N/A |
| 2023 | $269.24 Million | $2.43 Million | -$52.67 Million | 110.89x | N/A |
| 2024 | $156.33 Million | $4.35 Million | -$45.53 Million | 35.97x | N/A |
| 2025 | $208.13 Million | $4.71 Million | -$58.01 Million | 44.23x | N/A |
Competitor Companies of LUCD by Market Capitalization
Companies near Lucid Diagnostics Inc in the global market cap rankings as of September 18, 2026. Review LUCD tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lucid Diagnostics Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #126 globally with a market cap of $177.76 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #235 globally with a market cap of $107.45 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Abbott Laboratories | NYSE:ABT | $177.76 Billion | $102.23 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.77 |
| #235 | Stryker Corporation | NYSE:SYK | $107.45 Billion | $280.13 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Lucid Diagnostics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Lucid Diagnostics Inc's market cap moved from $1.03 Billion to $ 149.02 Million, with a yearly change of -42.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $149.02 Million | -28.40% |
| 2025 | $208.13 Million | +33.14% |
| 2024 | $156.33 Million | -41.94% |
| 2023 | $269.24 Million | +3.68% |
| 2022 | $259.69 Million | -74.67% |
| 2021 | $1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Lucid Diagnostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $149.02 Million USD |
| MoneyControl | $149.02 Million USD |
| MarketWatch | $149.02 Million USD |
| marketcap.company | $149.02 Million USD |
| Reuters | $149.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more